In vivo evidence that non-fused ETS factors cooperate with endogenous FET proteins to drive transcription from silent GGAA repeats is provided, mechanistically validating this regulatory transformation known to operate as an oncogenic mechanism beyond Ewing sarcoma.
Abstract
The conversion of transcriptionally silent GGAA microsatellites (GGAAµSats) into functional enhancers by FET::ETS oncogenic fusions is a hallmark of Ewing sarcoma. However, emerging evidence implicates non-fused, full-length oncogenic ETS transcription factors in activating these repeats in other malignancies. Evaluating the in vivo transcriptional requirements of various human ETS factors in Drosophila, we found that human ETV4 associates with and robustly activates GGAAµSats in a tissue-specific manner. This activation is strongly inhibited by the human ETS repressor ETV6. Taking advantage of low genetic redundancy in Drosophila, we identified Cabeza (Caz), the single fly FET ortholog, as a necessary cofactor for ETV4-mediated transcription at GGAAµSats. Conversely, EWS::FLI1-mediated transcriptional activation of GGAAµSats is entirely independent of endogenous Caz, highlighting the distinct mechanics of covalent tethering versus non-covalent physical complexes. Collectively, our findings provide in vivo evidence that non-fused ETS factors cooperate with endogenous FET proteins to drive transcription from silent GGAA repeats, mechanistically validating this regulatory transformation known to operate as an oncogenic mechanism beyond Ewing sarcoma.
New insights are revealed into how EWSR1::FLI1 binds to DNA motifs in chromatin and it is suggested that the EWSR1 LCD may contribute to both altered sequence-specific DNA binding and nucleosome engagement.
Ruo-Wen Chen, R. Zhou, E. J. Tokarsky et al.· Cancer Research· 0 citations
This work extensively characterized a CRISPR-engineered human hematopoietic stem and progenitor cell model of ASXL1 mutations, and is the first to functionally describe the mutant ASXL1 interactome in the context of human HSCs, identifying MECOM and BRD4 as actionable dependencies with therapeutic potential for ASXL1-m...
Madison L. Hall, Aliya Quintal, Sonia N. Acharya et al.· Blood· 0 citations
The identification of the splicing factor RBM39 as a vulnerability in ES is supported by the extraordinary sensitivity of these tumors to monotherapy with RBM39 degrader indisulam, highlighting the potential of this approach as a novel and promising therapeutic strategy for Ewing sarcoma.
Irene Cuervas, Sophie Bonnal, Evelyn Andrades et al.· bioRxiv· 0 citations
DNA-proximal phosphorylation of MYB is identified as a critical regulatory mechanism required for MYB oncogenesis through cooperative organization of transcription factors and nominated MYB N-terminal phosphorylation and its upstream kinases as candidate therapeutic targets for MYB-dependent leukemia.
Shu-Yuan Cheng, Katarzyna Kulej, Masahiro Uni et al.· Cancer Research· 0 citations
It is revealed that EWSR1::FLI1 possesses a key pioneer factor property, efficiently targeting its binding site within nucleosomes, and that full-length EWSR1::FLI1 binding shifts to preferentially target GGAA repeats, even on motifs that bind a single EWSR1::FLI1 protein.
Ruo-Wen Chen, R. Zhou, E. J. Tokarsky et al.· bioRxiv· 0 citations
This review summarizes classic and recent findings on structural biology, PTM networks, mutation landscapes, oncogenic mechanisms, and therapeutic frontiers, highlighting TWIST1 as a target for precision oncology and therapy.
B. R. Pires, G. Ferreira, Eliana Abdelhay· Biochimica et biophysica act...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.